Alzheimer's Drug Discovery Foundation and Target ALS Announce Partnership to Accelerate Biomarker Discovery and Development
The Alzheimer's Drug Discovery Foundation (ADDF) and Target ALS Foundation jointly announce their new Diagnostic Accelerator and Target ALS Foundation Biomarker Discovery RFP is now accepting letters of intent.
This RFP supports the identification and development of novel and peripheral and digital biomarkers for neurodegenerative diseases included Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Degeneration (FTD).
The duration of the award is a maximum two year period and the award amount is up to $300,00, with potential for follow on funding through a one-time award of up to $500,000 via a mission-related investment from the ADDG's Diagnostics Accelerator.